Background-Drug-eluting stents (DES) have been in clinical use for nearly a decade; however, the relative short-and long-term efficacy and safety of DES compared with bare-metal stents (BMS) and among the DES types are less well defined. with each other or against BMS for de novo coronary lesions, enrolling at least 100 patients and with follow-up of at least 6 months. Short-term (Յ1 year) and long-term efficacy (target-vessel revascularization, target-lesion revascularization) and safety (death, myocardial infarction, stent thrombosis) outcomes were evaluated and trial-level data pooled by both mixed-treatment comparison and direct comparison analyses. From 76 randomized clinical trials with 117 762 patient-years of follow-up, compared with BMS, each DES reduced long-term target-vessel revascularization (39%-61%), but the magnitude varied by DES type (EESϳSESϳZES-RϾPESϳZESϾBMS), with a Ͼ42% probability that EES had the lowest target-vessel revascularization rate. There was no increase in the risk of any long-term safety outcomes, including stent thrombosis, with any DES (versus BMS). In addition, there was reduction in myocardial infarction (all DES except PES versus BMS) and stent thrombosis (with EES versus BMS: Rate ratio, 0.51; 95% credibility interval, 0.35-0.73). The safest DES appeared to be EES (Ͼ86% probability), with reduction in myocardial infarction and stent thrombosis compared with BMS. Short-term outcomes were similar to long-term outcomes, with SES, ZES-R, and everolimus-eluting stent being the most efficacious and EES being the safest stent. Conclusions-DES are highly efficacious at reducing the risk of target-vessel revascularization without an increase in any safety outcomes, including stent thrombosis. However, among the DES types, there were considerable differences, such that EES, SES, and ZES-R were the most efficacious and EES was the safest stent. (Circulation. 2012;125:2873-2891.)
everolimus [EES], zotarolimus [ZES]
, and ZES-Resolute [ZES-R]) compared with BMS and against each other are not well defined. Recent studies and analyses have tended to compare one DES against a comparator encompassing all other DES, which makes a hierarchical comparison of the relative efficacy and safety of each of the DES problematic. Whether any one DES is measurably different in its efficacy and safety is a topic of great interest to physicians and patients. Although each of the DES has had claims of superior efficacy or safety, direct comparisons have been limited. The objective of the present analysis was to evaluate the relative efficacy and safety of the currently available DES versus BMS and against each other for both short-and long-term outcomes using mixed-treatment comparison (MTC) analyses.
Methods Eligibility Criteria
We conducted PubMed, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) searches for randomized clinical trials using the terms, "drug-eluting stent" and "bare metal stent" and using the names of individual drug-eluting stents (SES, PES, EES, ZES, and ZES-R) until March 2012 (Week 2). The MeSH terms are listed in online-only Data Supplement Table I . We checked the reference lists of review articles, meta-analyses, and original studies identified by the electronic searches to find other eligible trials. There was no language restriction for the search. In addition, we searched conference proceedings/abstracts of the following societies: American Heart Association, American College of Cardiology, Transcatheter Cardiovascular Therapeutics, Society of Cardiovascular Angiography and Intervention, European Society of Cardiology, and Euro-PCR. For studies that did not report outcomes of interest, we contacted the authors via email. Additionally, we searched the FDA dockets, searching all documents submitted for device approval by hand, as well as the FDA meeting minutes, which are available on the FDA's Web site.
Eligible trials had to fulfill the following criteria: (1) Randomized clinical trials comparing the above durable polymer and stent DES with BMS or against each other, in patients undergoing percutaneous coronary intervention of a de novo coronary lesion; (2) follow-up of at least 6 months; (3) enrollment of at least 100 patients; and (4) ability to report the outcomes of interest (below). Trials that used DES with an eluting drug other than those compared (as listed in the Methods), balloon angioplasty alone, or comparison with coronary artery bypass graft surgery were excluded. In addition, we excluded trials that tested 2 stents that eluted the same drug but differed in stent designs (PERSEUS [Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System], 8 PIPA [Comparison of Paclitaxel-Eluting Coroflex Please Stent Versus Paclitaxel-Eluting Stent], 9 and the PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions 10 ) because these trials did not provide head-to-head comparisons of 2 different DES or DES versus BMS. 11, 12 
Selection and Quality Assessment
Four authors (S.B., S.K., M.F., and N.A.) independently assessed trial eligibility and trial bias risk and extracted data. Disagreements were resolved by consensus. The bias risk of trials were assessed with the components recommended by the Cochrane Collaboration 13 : Sequence generation of the allocation; allocation concealment; blinding of participants, personnel, and outcome assessors; incomplete outcome data; selective outcome reporting; and other sources of bias. Trials with high or unclear risk for bias for any 1 of the first 3 components were considered trials with high risk of bias. Otherwise, they were considered trials with low risk of bias.
Data Extraction and Synthesis
Short (Յ1 year) and long-term (Ͼ1 year) efficacy and safety outcomes were evaluated. Efficacy outcomes were target-vessel revascularization (TVR) and target-lesion revascularization (TLR). Safety outcomes were death, myocardial infarction (MI), and stent thrombosis. Three types of stent thrombosis were evaluated: "Any" stent thrombosis (based on trial stent thrombosis definition), Academic Research Consortium (ARC)-defined "definite" or "probable" stent thrombosis, and ARC-defined "definite" stent thrombosis. For short-term outcomes, the outcomes closest to 1 year were abstracted. For long-term outcomes, the longest reported follow-up events, including short-term outcomes, were abstracted.
Statistical Analyses

Mixed-Treatment Comparisons
Bayesian hierarchical random effects models 14 for MTC meta-analysis were used to compare the different stent types. 15 This was performed with WinBUGS code validated by the UK Medical Research Council Health Services Research Collaboration. 16 The MTC allows for comparisons of agents not directly addressed within any of the individual trials. In addition to analyzing the direct within-trial comparisons between 2 stents (such as stent A versus B), the MTC framework enabled us to incorporate the indirect comparisons constructed from 2 trials that had 1 stent type in common (such as comparison of stent A versus C using trials comparing A versus B and B versus C). This type of analysis has the advantage of maintaining the within-trial randomized treatment comparison of each trial while combining all available comparisons between treatments. The MTC analysis produces tighter credibility intervals (CrI, analogous to the confidence interval of frequentist methodology), which implies greater precision of the estimates than the direct comparison analysis. 17 For the purpose of analysis, the 6 stent types were defined: BMS, SES, PES, EES, ZES, and ZES-R. The primary analysis compared each individual DES to BMS, which was used as reference. For the short-term outcome analyses, outcomes at or within 1 year were evaluated. For the long-term analysis, given the variability in the length of follow-up for each of these trials, the analysis used the rate of efficacy and safety outcomes per 1000 person-years to obtain the log rate ratios of 1 stent relative to another. For long-term outcomes, a random-effects Poisson regression model was fitted, taking into account the correlation structure induced by the multiarm trials. 18 A randomeffects rather than a fixed-effect model was used because this was likely the most appropriate and conservative analysis to account for differences between trials. Rates, rather than number of events, were consid- *Represents risk of bias based on sequence generation of allocation, allocation concealment, and blinding. ϩ Indicates low bias risk; Ϫ, high bias risk; and Ϯ, unclear bias risk.
ered the most appropriate outcome for long-term analyses because they incorporate the duration of the trials, which was variable. One record per treatment group per study was used, and the outcome on the Poisson regression model was counts of events.
Calculation of the probability that each treatment is best (lowest event proportion) was performed with a bayesian Markov Chain Monte Carlo method, adapted to apply to a connected network set of treatment comparisons. Minimally informative prior distributions were used for log rate ratios and for random effects standard deviations, so the findings are close to those obtained with frequentist methods. All network analyses were conducted with WinBUGS 1.4.3. The relative efficacy and safety of the stents were compared with MTC and using the probability that a stent had the lowest event proportion (as described above).
Direct Comparison
An intention-to-treat meta-analysis was performed in line with recommendations from the Cochrane Collaboration and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement 13, 19 using standard software (Stata 9.0, Stata Corp, College Station, TX). 20 Heterogeneity was assessed with the I 2 statistic. 21 I 2 is the proportion of total variation observed between the trials attributable to differences between trials rather than sampling error (chance), with I 2 Ͻ25% considered low and I 2 Ͼ75% high. The pooled effect for each grouping of trials was derived from the point estimate for each separate trial weighted by the inverse of the variance (1/SE 2 ). Risk ratio was calculated with the random-effects model of DerSimonian and Laird. 22 
Sensitivity Analyses
To test for the robustness of the primary analyses, several sensitivity analyses were performed. Analyses were restricted to the following: (1) Trials with low-bias risk. (2) Trials with no routine angiographic follow-up, to avoid bias caused by oculostenotic reflex and a higher revascularization rates in trials with routine angiographic follow-up. For the purpose of the present analysis, routine angiographic follow-up was defined as trials in which Ͼ50% of patients received routine angiography during follow-up. (3) Trials limited to patients without acute coronary syndrome, to avoid a confounding effect of an acute coronary syndrome subgroup. An acute coronary syndrome trial was defined as a trial in which Ͼ50% of patients enrolled had acute coronary syndrome (unstable angina, non-ST-segment-elevation myocardial infarction, or ST-segment-elevation myocardial infarction) as the reason for percutaneous coronary intervention. (4) Trials in which the duration of clopidogrel in the DES arm was at least 6 months, to avoid a confounding effect of shorter-duration clopidogrel treatment on safety outcomes.
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Results
Study Selection
We identified 77 randomized clinical trials that satisfied our inclusion criteria (Figure 1) . We included the paclitaxel slowrelease stent (SR) as opposed to the paclitaxel moderate-release stent arm of the TAXUS II trial because paclitaxel SR is the currently used paclitaxel stent type. We excluded the ZoMaxx I 24 and II 25 trials because the ZoMaxx stent is a different ZES stent platform (TriMaxx; Abbott Laboratories; stainless steeltantalum stent platform to deliver zotarolimus 10 g/mm via phosphorylcholine polymer system). Similarly, we excluded the ISAR (Intracoronary Stenting and Antithrombotic Regimen) Test 1 26 trial because it tested a non-polymer-based rapamycineluting stent. The ISAR Test 2 27 data included were the SES and ZES arms only, with the polymer-free dual-DES arm of the trial excluded. The network of available treatment comparisons is shown in Figure 2 .
Baseline Characteristics
The baseline characteristics and quality analysis are described in Tables 1 and 2 . 28 -123 The 76 trials enrolled 57 138 patients with 117 762 patient-years of follow-up. Eight trials were 3-arm trials, but the remainder were 2-arm trials. Fifty-three trials were considered trials with low-bias risk and the rest were intermediate-or high-bias risk trials. Of the 76 trials, 61 used clopidogrel for at least 6 months in the DES arm (Table 2) . Mean follow-up duration was 2.1 years (range, 0.5-5 years).
Short-Term Outcomes (<1 Year)
Short-Term Efficacy
Compared with BMS (reference odds ratio of 1), all of the DES reduced TVR by 52% to 74% ( Figure 3A ), but the magnitude of this reduction varied by DES type. Compared with SES, EES and ZES-R had similar efficacy but PES and ZES were less efficacious at reducing TVR ( Figure 3A) . Similarly, compared with PES, ZES had similar efficacy but EES was more efficacious, with a 40% decrease in the odds of TVR ( Figure 3A) . Compared with EES, ZES-R had similar efficacy, but ZES had higher odds of TVR (by efficacy, SESϳZES-RϳEESϾPESϳZESϾBMS). Table 3 summarizes the rate of TVR and the probability that each stent is the best (lowest event proportion). Among the stents, there was a Ͼ58% probability that SES had the lowest TVR rate compared with the other stents (Table 3) , followed by ZES-R (probability 24%) and EES (probability 17%). The median TVR rate with BMS was 15.76%, and there was a Ͼ11% absolute decrease in the rate with the most efficacious DES (SES; TVR rate of 4.11%; number needed to treat, 8).
The results were largely similar in the sensitivity analysis performed based on trial quality (online-only Data Supplement Table II) , angiographic follow-up (online-only Data Supplement Table III) , non-acute coronary syndrome trials (online-only Data Supplement Table IV), in trials with Ͼ6 months of clopidogrel use (online-only Data Supplement Figure I ), and in the direct comparison analysis (online-only Data Supplement Table V ). In addition, the results were largely similar for the outcome of TLR ( Figure 3B ).
Short-Term Safety
Compared with BMS (reference odds ratio of 1), there was no increase in death with any of the DES ( Figure 4A) , with similar nondifferences for any pair of between-DES comparisons ( Figure 4A ). The median short-term death rate was Ͻ0.3% for all stents (Table 3) .
Compared with BMS (reference odds ratio of 1), there were significant reductions (33%-45%) in the odds of MI with all DES except PES, for which there was no significant difference. For the between-DES comparisons, PES was inferior compared with SES, EES, ZES, and ZES-R, but there were no differences for other pairs of DES comparisons (SESϳEESϳZESϳZES-RϾBMSϳPES; Figure 4B ). Among the stents, there was a Ͼ46% probability that ZES-R had the lowest MI rate, followed very closely by EES compared with the other stents ( Table 3 ). The median MI rate with BMS was 4.23%, and there was a 1.92% absolute decrease with the safest DES (ZES-R, MI rate of 2.30%; number needed to treat, 52; Table 3 ).
Compared with BMS (reference odds ratio of 1), there was no increase in the odds of any stent thrombosis with any DES, with a 56% reduction in the odds with EES ( Figure 5A ). For the between-DES comparisons, EES decreased the odds of any stent thrombosis compared with SES, PES, and ZES, with no differences for other pairs of DES comparisons ( Figure 5A ). Among the stents, there was a Ͼ80% probability that EES had the lowest "any" stent thrombosis rate compared with other stents (Table  3 ). The median "any" stent thrombosis rate was Ͻ0.2% with all stents, 0.18% with BMS, and Ͻ0.10% with the safest DES (EES; rate of 0.08%; number needed to treat, 1000; Table 3 ). In a sensitivity analysis restricted to trials with clopidogrel duration Ͼ6 months, EES was better than BMS, PES, and ZES, with no difference for other combinations of stent comparisons (including ZES-R; online-only Data Supplement Figures V and VI) . The results were largely similar for the outcomes of definite or probable stent thrombosis ( Figure 5B ) and definite stent thrombosis ( Figure 5C ). For all of the above analyses, sensitivity analyses, including in trials with Ͼ6 months of clopidogrel use (online-only Data Supplement Tables II through IV and Figures  II through 
Long-Term Outcomes
Long-Term Efficacy
Compared with BMS (reference rate ratio of 1), the shortterm benefits with DES were also preserved long-term, with a 39% to 61% reduction in the rate of TVR with any DES (Figure 6A ), but the magnitude of this reduction varied with DES type (EESϳSESϳZES-RϾPESϳZESϾBMS). There was a Ͼ42% probability that EES had the lowest TVR rate ( Table 4 ). The median TVR rate with BMS was 89 per 1000 patient-years of follow-up, and the rate with the most efficacious DES (EES) was 34 per 1000 patient-years (Table 4) . The results were largely similar in the sensitivity analyses, including in trials with Ͼ6 months of clopidogrel use (onlineonly Data Supplement Tables VI through VIII and Figure  VII) , in direct comparison analysis (online-only Data Supplement Table IX) , and for the outcome of TLR ( Figure 6B ).
Long-Term Safety
Similar to results regarding short-term death, there was no increase in death long-term with any of the DES or among any pair of DES comparisons ( Figure 7A ). As with short-term MI, consistent results were seen long-term, with a significant reduction (18%-37%) in the rate of MI with all DES (compared with BMS) except PES, for which there was no difference. There were differences between DES comparisons such that EESϳZESϳZES-RϾSESϾPESϳBMS ( Figure 7B ). Among the stents, there was a Ͼ46% probability that EES had the lowest MI rate (Table 4) .
Long-term any stent thrombosis rates were no different for most DES compared with BMS, except for EES, for which there was a 49% reduction in the rate ratio of stent thrombosis ( Figure 8A ). For the between-DES comparisons, SES was better than PES and EES was better than SES, PES, and ZES, with no differences for other sets of DES comparisons (including ZES-R; Figure 8A ). Among the stents, there was a Ͼ86% probability that EES had the lowest "any" stent thrombosis rate (Table 4 ). The results were largely similar for the outcomes of definite or probable stent thrombosis ( Figure  8B ) and definite stent thrombosis ( Figure 8C ).
For all of the above analyses, sensitivity analyses, including in trials with Ͼ6 months of clopidogrel use (online-only Data Supplement Tables VI through XII), and direct comparison analysis (online-only Data Supplement Table IX) yielded consistent results.
Discussion
The results of the present study with data from Ͼ100 000 patient-years of follow-up showed that DES are highly efficacious at reducing not only the short-term risk but also the long-term risk of TVR/TLR without an increase in any safety outcomes, including stent thrombosis, compared with BMS. In fact, there was a significant reduction in both shortand long-term risk of stent thrombosis with the safest DES (EES) compared with BMS. In addition, each DES, except for PES, reduced the short-and long-term risk of MI compared with BMS. Moreover, significant differences were also observed among DES types both for efficacy and safety, with evidence suggesting that EES, SES, and ZES-R had the best long-term safety and efficacy among the studied stent types.
Efficacy of DES
The introduction of DES has resulted in a dramatic reduction in both angiographic restenosis and the need for repeat revascularization compared with BMS. This benefit is explained by the inhibition of fibromuscular hyperplasia through targeted delivery of cytostatic/cytotoxic drugs. However, the drug eluted, the kinetics of elution, and the duration of elution vary with DES type. Moreover, in addition to the drug, various other stent characteristics determine its efficacy at reducing restenosis, including strut thickness, stent mate- rial, type of polymer, and drug-release kinetics. 124 Newer DES (everolimus, zotarolimus) have biocompatible polymers, different drugs (everolimus, zotarolimus), and new stent platforms (cobalt chromium, nickel chromium) with thinner struts and polymers.
The present analysis showed that DES reduced the risk of TVR/TLR compared with BMS, which is not surprising; however, the magnitude of this reduction varied with DES type. Our probability analysis allowed for a relative scaling of the stents such that for efficacy, EES, SES, and ZES-R were the most efficacious stents (in that order). The data for ZES-R are supported by 2 trials thus far (Resolute All Comers and TWENTE [The Real-World Endeavor Resolute Versus XIENCE V Drug-Eluting Stent Study in Twente]), both of which showed noninferiority against EES. The present results are consistent with these trials.
In our sensitivity analysis, we excluded trials in which there was routine angiographic follow-up. Prior studies have shown an increased rate of repeat revascularization, even in the absence of symptoms or objective evidence of ischemia, in trials with routine angiographic follow-up, perhaps because of an oculostenotic reflex. Our sensitivity analysis in the subset of trials without angiographic follow-up showed consistent results as that of the primary analyses. In addition, we showed consistent results across a wide spectrum of sensitivity/subgroup analyses.
Safety of DES
Despite the considerable efficacy of DES at reducing the risk of in-stent restenosis, the possibility of an increased risk of stent thrombosis, especially very late stent thrombosis, has been an important safety concern with DES. [125] [126] [127] [128] [129] Because inhibition of smooth muscle cell proliferation by currently available DES is inseparably connected with the inhibition of endothelial cell proliferation, delayed and incomplete healing has been hypothesized to result in the propensity for stent thrombosis. BMS has therefore been the benchmark for safety standards for stent evaluation. The results of the present analysis showed no increase in the risk of stent thrombosis with DES with appropriate concomitant antiplatelet therapy.
In fact, there was a reduction in the risk of stent thrombosis with EES, both short-and long-term, compared with BMS. The results were consistent when trials with Ͼ6 months of clopidogrel duration in the DES arm were separately analyzed. The reduced risk of stent thrombosis with EES compared with BMS is difficult to explain but could result from extended dual-antiplatelet therapy with DES in contemporary cohorts compared with BMS. In addition, late and very late stent thrombosis with BMS is not as uncommon as once believed. 130, 131 Moreover, newer-generation stents such as the EES and ZES-R have changes in stent design, including thinner struts, use of cobalt-chromium rather than stainless steel stents, and thinner and more biocompatible polymers that may elicit less inflammatory response with a consequent decrease in stent thrombosis. The present results are consistent with similar low rates of stent thrombosis with EES seen in the Bern-Rotterdam cohort study (versus other DES) 132 and in an updated analysis from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR), 133 in which there was a 67% reduction in the risk of stent thrombosis compared with BMS. In our probability analyses, EES had a Ͼ80% probability of having the lowest stent thrombosis rate compared with all other stent types. In both the Resolute All Comers and the TWENTE trials, ZES-R was noninferior to EES for safety outcomes, including stent thrombosis. However, in the Resolute All Comers trial, ZES-R was associated with a higher definite stent thrombosis at 1 year than EES (1.2% versus 0.3%; Pϭ0.01), with a trend toward higher definite or probable stent thrombosis at 2 years (1.9% versus 1.0%; Pϭ0.08). Whether this is caused by the play of chance should be determined in future trials.
There was no short-or long-term increase in death with any DES compared with BMS. In addition, there was a significant reduction in MI with DES (except PES) compared with BMS. Studies have shown that restenosis is not benign and is associated with increased risk of MI and death. 130, 134 The short-and long-term reduction in the risk of MI with DES was likely caused by a reduction in the risk of restenosis. In addition, it is possible that the extended duration of dual-antiplatelet therapy with DES may have a role in reduction of MI. Data from the CHARISMA trial (Clopidogrel for High Atherothrombotic Risk and Ischemia Stabilization, Management, and Avoidance) have shown that dual-antiplatelet therapy reduced the risk of primary outcome (stroke, MI, or cardiovascular death) in the prespecified subgroup of patients with documented cardiovascular disease. 135, 136 However, other trials in patients undergoing percutaneous coronary intervention have not shown similar benefit of extended dual-antiplatelet therapy, although these were likely to be underpowered to detect a difference. 137 Although the platinum chromium EES stent was not evaluated in the present analysis, in the PLATINUM trial this was noninferior to the cobalt chromium EES for efficacy and safety end points. 138 The results of the present meta-analysis are therefore likely applicable to the platinum chromium EES.
Study Limitations
As in other meta-analyses, given the lack of data in each trial, we did not adjust our analyses for stent dimensions, clopidogrel duration, or other medication usage or their doses. In addition, we did not adjust our analysis for any study-specific or treatment-specific covariates. Although detailed sensitivity analyses on many variables were undertaken, given heterogeneity in the study protocols, clinically relevant differences could have been missed and are best assessed in a meta-analysis of individual patient data. In addition, technical improvements over time and improvements in medical management were not accounted for in the analyses. Moreover, we used the trial definition of MI, although this was clearly not uniform across all trials. Not all of the trials reported each of the outcomes we assessed; accordingly, we are not able to exclude outcome measure reporting bias. Our analyses did not correct for multiple testing. The results of the sensitivity analyses are best described as secondary and hypothesis generating only. The differences seen within DES types are only applicable to the specific stents evaluated in the present study. Nonetheless, this study, which is the largest meta-analysis comparing DES and BMS, offers important insights into their relative safety and efficacy.
Conclusions
DES are highly efficacious at reducing the short-and long-term risk of TVR/TLR without any increase in any safety outcomes, including stent thrombosis, compared with BMS. In fact, each DES except for PES significantly reduced the rate of MI compared with BMS. However, within the types of DES, there were considerable differences in outcomes, such that EES, SES, and ZES-R were the most effective in terms of TVR/TLR and EES was the safest in terms of stent thrombosis for long-term outcomes. ACS = acute coronary syndromes; Cr I = credibility interval; MI = myocardial infarction; OR = odds ratio; ST = stent thrombosis; TVR= target vessel revascularization; Zotarolimus-R = Zotarolimus-Resolute
Disclosures
The only 2 trials that tested Zotarolimus-R were categorized as ACS trials as they had greater percentage of ACS patients than non-ACS. Hence no estimate for Zotarolimus-R for non-ACS trials. 
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